Literature DB >> 10099127

Mucosal vaccination strategies for women.

P A Kozlowski1, S Cu-Uvin, M R Neutra, T P Flanigan.   

Abstract

Women were immunized orally, rectally, or vaginally with a recombinant cholera toxin B-containing vaccine to determine which of these mucosal immunization routes generate the greatest levels of antibody in the female genital tract and rectum. ELISA was used to measure concentrations of cholera toxin B-specific IgA and IgG antibody in serum and secretions before and after three immunizations. Each immunization route similarly increased specific IgG in serum and specific IgA in saliva. Only the vaginal route increased IgA antibodies in genital tract secretions and could be shown to induce a local IgG response. However, vaginal immunization failed to produce antibody in the rectum. In a similar fashion, rectal immunization elicited highest concentrations of locally derived IgA and IgG antibody in the rectum but was ineffective for generating antibody in the genital tract. The data suggest that local immunization may induce the greatest immune responses in the female genital tract and rectum of humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10099127     DOI: 10.1086/314810

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

Review 1.  Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Expert Opin Biol Ther       Date:  2010-08       Impact factor: 4.388

2.  Vaccine delivery by polymeric vehicles in the mouse reproductive tract induces sustained local and systemic immunity.

Authors:  Patricia Kuo-Haller; Yen Cu; Jeremy Blum; Judith A Appleton; W Mark Saltzman
Journal:  Mol Pharm       Date:  2010-08-26       Impact factor: 4.939

3.  Chitosan enhances nanoparticle delivery from the reproductive tract to target draining lymphoid organs.

Authors:  Jaehyung Park; Renuka Ramanathan; Linhchi Pham; Kim A Woodrow
Journal:  Nanomedicine       Date:  2017-04-20       Impact factor: 5.307

4.  Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans.

Authors:  Lotta Wassen; Marianne Jertborn
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

5.  Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization.

Authors:  Waleed Mustafa; Paulo Cesar Maciag; Zhen-kun Pan; Jessica R Weaver; Yuhong Xiao; Stuart N Isaacs; Yvonne Paterson
Journal:  Viral Immunol       Date:  2009-06       Impact factor: 2.257

6.  Influence of exogenous reproductive hormones on specific antibody production in genital secretions after vaginal vaccination with recombinant cholera toxin B subunit in humans.

Authors:  Lotta Wassen; Marianne Jertborn
Journal:  Clin Vaccine Immunol       Date:  2006-02

7.  Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges.

Authors:  Katherine H Parker; Troy J Kemp; Yuanji Pan; Zhen Yang; Anna R Giuliano; Ligia A Pinto
Journal:  Vaccine       Date:  2018-04-06       Impact factor: 3.641

8.  Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.

Authors:  Martin P Cranage; Carol A Fraser; Alethea Cope; Paul F McKay; Michael S Seaman; Tom Cole; A Nasir Mahmoud; Joanna Hall; Elaine Giles; Gerald Voss; Mark Page; Neil Almond; Robin J Shattock
Journal:  Vaccine       Date:  2010-12-25       Impact factor: 3.641

9.  Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels.

Authors:  Troy J Kemp; Mahboobeh Safaeian; Samantha Miner; Marcus C Williams; Ana Cecilia Rodriguez; Rolando Herrero; Allan Hildesheim; Ligia A Pinto
Journal:  Front Oncol       Date:  2012-06-25       Impact factor: 6.244

10.  Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Authors:  Ann J Hessell; Eva G Rakasz; Pascal Poignard; Lars Hangartner; Gary Landucci; Donald N Forthal; Wayne C Koff; David I Watkins; Dennis R Burton
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.